Article
Silver Spring, Md. - The FDA Dermatologic and Ophthalmic AdvisoryCommittee, by an 8-2 vote, on May 23 recommended approval of alefacept,a systemic drug for the treatment of chronic plaque psoriasis.
Conference Recap: 2024 Society of Dermatology Physician Associates Fall Dermatology Conference
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881
Review Compares Psoriasis Therapies in Asian Populations